Population pharmacokinetic-pharmacodynamic analysis of trastuzumab-associated cardiotoxicity.
about
Pharmacodynamic modeling of adverse effects of anti-cancer drug treatmentS100A1 as a Potential Diagnostic Biomarker for Assessing Cardiotoxicity and Implications for the Chemotherapy of Certain Cancers.Integrated Simulation Framework for Toxicity, Dose Intensity, Disease Progression, and Cost Effectiveness for Castration-Resistant Prostate Cancer Treatment With EribulinPharmacokinetics of Selected Anticancer Drugs in Elderly Cancer Patients: Focus on Breast Cancer.Antibody Therapeutics in Oncology.Optimizing drug development of anti-cancer drugs in children using modelling and simulation.Population pharmacokinetic-pharmacodynamic analysis for eribulin mesilate-associated neutropenia.Use of population approach non-linear mixed effects models in the evaluation of biosimilarity of monoclonal antibodies.Integrated semi-physiological pharmacokinetic model for both sunitinib and its active metabolite SU12662.Optimizing anticancer drug treatment in pregnant cancer patients: pharmacokinetic analysis of gestation-induced changes for doxorubicin, epirubicin, docetaxel and paclitaxel.Mathematical modeling of efficacy and safety for anticancer drugs clinical development.Pharmacodynamic modeling of cardiac biomarkers in breast cancer patients treated with anthracycline and trastuzumab regimens.Trastuzumab induced cardiotoxicity in HER2 positive breast cancer patients attended in a tertiary hospital.CATCH-KB: Establishing a Pharmacogenomics Variant Repository for Chemotherapy-Induced Cardiotoxicity.
P2860
Q26766318-AE7D8C8D-B9E3-4FA0-886E-D0714A2B696AQ35872865-DDCC4B5A-53A1-413D-8EF2-63E8B2817B09Q35979543-B01097B7-622F-4C97-AA42-2451E53EF5DDQ36506987-783DB9B6-BB23-4194-8A32-8C14A03391E1Q36791878-34AD69B2-1240-4D08-8665-689F9AF68E69Q36987975-5FAF6AB0-8B37-417F-8518-66268DA8255CQ37161899-C1E6DD6B-BB5A-41C7-8507-BAD2D78AEE37Q37322523-DBBCBA10-45FC-4E78-AEF9-8C0F1E3C7C85Q40126912-12AB6CA1-469B-417D-ABCB-EBF2D7B7F7ECQ43464645-784FD29F-C555-412E-9B7A-2C955095D167Q47663303-8675BC90-1836-43BE-8067-F2A6F9908D79Q50079226-6519ED56-E49B-4D26-B7ED-645011B987DEQ50589569-7284D9EC-C6C9-4185-8D99-5D5B9DCEF2CAQ55208199-964CBE3E-7917-4FCD-A674-437EF5986859
P2860
Population pharmacokinetic-pharmacodynamic analysis of trastuzumab-associated cardiotoxicity.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Population pharmacokinetic-pha ...... mab-associated cardiotoxicity.
@ast
Population pharmacokinetic-pha ...... mab-associated cardiotoxicity.
@en
Population pharmacokinetic-pha ...... mab-associated cardiotoxicity.
@nl
type
label
Population pharmacokinetic-pha ...... mab-associated cardiotoxicity.
@ast
Population pharmacokinetic-pha ...... mab-associated cardiotoxicity.
@en
Population pharmacokinetic-pha ...... mab-associated cardiotoxicity.
@nl
prefLabel
Population pharmacokinetic-pha ...... mab-associated cardiotoxicity.
@ast
Population pharmacokinetic-pha ...... mab-associated cardiotoxicity.
@en
Population pharmacokinetic-pha ...... mab-associated cardiotoxicity.
@nl
P2093
P2860
P356
P1476
Population pharmacokinetic-pha ...... mab-associated cardiotoxicity.
@en
P2093
A D R Huitema
A H Boekhout
J G C van Hasselt
J H Beijnen
J H M Schellens
P2860
P304
P356
10.1038/CLPT.2011.74
P407
P577
2011-06-01T00:00:00Z